MedPath

The effect of high DHA/EPA PUFA and ascorbic acid in the treatment of refractory epileptic patients

Phase 2
Recruiting
Conditions
seizure.
Epilepsy and recurrent seizures
Registration Number
IRCT20240220061057N1
Lead Sponsor
Ardabil University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Epileptic patients who take at least two antiepileptic drugs but have had at least one seizure in the last 6 months.
Patients are at least 18 years old
Willingness to participate in the study

Exclusion Criteria

pregnancy
chronic kidney disease
history of MI or vascular interventions
history of renal stone
use of anticoagulants
history of allergy to ascorbic acid or DHA/EPA PUFA
history of familial or acquired dyslipidemia
The patient unwillingness to continue the combined treatment

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath